At a glance
ClinicalIndex Comparison RecordN/ACompleted· 727 enrolled
Drug / intervention
botulinum toxin Type Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea
In Brief
An observational study evaluating botulinum toxin Type A for Hyperhidrosis and 2 related conditions. Completed, enrolled 727 participants across 1 site.
Detailed Summary
This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal spasticity or moderate to severe glabellar lines in clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHyperhidrosis, Muscle Spasticity, Glabellar Lines
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
Primary CompletionApr 2012
First PostedJan 2014
TodayJul 2026
First PostedJan 23, 2014
Enrollment StartJul 1, 2008
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 12.4 years ago
Interventions
botulinum toxin Type Abiological
Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.